These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

228 related articles for article (PubMed ID: 26934461)

  • 1. Inhibitor Response to HER2 G776(YVMA) In-frame Insertion in HER2-positive Breast Cancer.
    Zheng YB; Yu Y; Chen B; Hu JL; Jing T; Zhang XP
    Cancer Invest; 2016; 34(3):123-9. PubMed ID: 26934461
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A systematic analysis of the resistance and sensitivity of HER2YVMA receptor tyrosine kinase mutant to tyrosine kinase inhibitors in HER2-positive lung cancer.
    Shen X; Chen B; Ma Z; Xie B; Cao X; Yang T; Zhao Y; Qin J; Li J; Cao F; Chen X
    J Recept Signal Transduct Res; 2016; 36(1):89-97. PubMed ID: 26391018
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Combination of In Silico Analysis and In Vitro Assay to Investigate Drug Response to Human Epidermal Growth Factor Receptor 2 Mutations in Lung Cancer.
    Yu X; Wang T; Lou Y; Li Y
    Mol Inform; 2016 Jan; 35(1):25-35. PubMed ID: 27491651
    [TBL] [Abstract][Full Text] [Related]  

  • 4. HER2 kinase domain mutation results in constitutive phosphorylation and activation of HER2 and EGFR and resistance to EGFR tyrosine kinase inhibitors.
    Wang SE; Narasanna A; Perez-Torres M; Xiang B; Wu FY; Yang S; Carpenter G; Gazdar AF; Muthuswamy SK; Arteaga CL
    Cancer Cell; 2006 Jul; 10(1):25-38. PubMed ID: 16843263
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Drug response to HER2 gatekeeper T798M mutation in HER2-positive breast cancer.
    Meng X; Li Y; Tang H; Mao W; Yang H; Wang X; Ding X; Xie S
    Amino Acids; 2016 Feb; 48(2):487-97. PubMed ID: 26439378
    [TBL] [Abstract][Full Text] [Related]  

  • 6. HER2 insertion YVMA mutant lung cancer: Long natural history and response to afatinib.
    Li BT; Lee A; O'Toole S; Cooper W; Yu B; Chaft JE; Arcila ME; Kris MG; Pavlakis N
    Lung Cancer; 2015 Dec; 90(3):617-9. PubMed ID: 26559459
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Targeting
    Han H; Li S; Chen T; Fitzgerald M; Liu S; Peng C; Tang KH; Cao S; Chouitar J; Wu J; Peng D; Deng J; Gao Z; Baker TE; Li F; Zhang H; Pan Y; Ding H; Hu H; Pyon V; Thakurdin C; Papadopoulos E; Tang S; Gonzalvez F; Chen H; Rivera VM; Brake R; Vincent S; Wong KK
    Cancer Res; 2021 Oct; 81(20):5311-5324. PubMed ID: 34380634
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Atomistic insights into the lung cancer-associated L755P mutation in HER2 resistance to lapatinib: a molecular dynamics study.
    Yang B; Zhang H; Wang H
    J Mol Model; 2015 Feb; 21(2):24. PubMed ID: 25620423
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Activity of a novel HER2 inhibitor, poziotinib, for HER2 exon 20 mutations in lung cancer and mechanism of acquired resistance: An in vitro study.
    Koga T; Kobayashi Y; Tomizawa K; Suda K; Kosaka T; Sesumi Y; Fujino T; Nishino M; Ohara S; Chiba M; Shimoji M; Takemoto T; Suzuki M; Jänne PA; Mitsudomi T
    Lung Cancer; 2018 Dec; 126():72-79. PubMed ID: 30527195
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Impact of common epidermal growth factor receptor and HER2 variants on receptor activity and inhibition by lapatinib.
    Gilmer TM; Cable L; Alligood K; Rusnak D; Spehar G; Gallagher KT; Woldu E; Carter HL; Truesdale AT; Shewchuk L; Wood ER
    Cancer Res; 2008 Jan; 68(2):571-9. PubMed ID: 18199554
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Lapatinib: a small-molecule inhibitor of epidermal growth factor receptor and human epidermal growth factor receptor-2 tyrosine kinases used in the treatment of breast cancer.
    Tevaarwerk AJ; Kolesar JM
    Clin Ther; 2009; 31 Pt 2():2332-48. PubMed ID: 20110044
    [TBL] [Abstract][Full Text] [Related]  

  • 12. HER2 overexpression increases sensitivity to gefitinib, an epidermal growth factor receptor tyrosine kinase inhibitor, through inhibition of HER2/HER3 heterodimer formation in lung cancer cells.
    Hirata A; Hosoi F; Miyagawa M; Ueda S; Naito S; Fujii T; Kuwano M; Ono M
    Cancer Res; 2005 May; 65(10):4253-60. PubMed ID: 15899817
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Discovery of Potent and Selective Covalent Inhibitors of HER2
    Hicken EJ; Brown K; Dwulet NC; Gaudino JJ; Hansen EP; Hartley DP; Kowalski JP; Laird ER; Lazzara NC; Li B; Mou TC; Mutryn MF; Oko L; Pajk S; Pipal RW; Rosen RZ; Shelp R; Singh A; Wang J; Wise CE; Wong C; Wong JY
    J Med Chem; 2024 Jun; 67(11):9759-9771. PubMed ID: 38820338
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Breast cancer expressing the activated HER2/neu is sensitive to gefitinib in vitro and in vivo and acquires resistance through a novel point mutation in the HER2/neu.
    Piechocki MP; Yoo GH; Dibbley SK; Lonardo F
    Cancer Res; 2007 Jul; 67(14):6825-43. PubMed ID: 17638894
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Molecular insight into the T798M gatekeeper mutation-caused acquired resistance to tyrosine kinase inhibitors in ErbB2-positive breast cancer.
    Lu J; Zhou K; Yin X; Xu H; Ma B
    Comput Biol Chem; 2019 Feb; 78():290-296. PubMed ID: 30605854
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Specific
    Yang G; Xu H; Hu J; Liu R; Hu P; Yang Y; Li W; Hao X; Zhang S; Xu F; Ai X; Li J; Wang Y
    Front Pharmacol; 2022; 13():806737. PubMed ID: 35330827
    [No Abstract]   [Full Text] [Related]  

  • 17. Lapatinib: a dual inhibitor of human epidermal growth factor receptor tyrosine kinases.
    Medina PJ; Goodin S
    Clin Ther; 2008 Aug; 30(8):1426-47. PubMed ID: 18803986
    [TBL] [Abstract][Full Text] [Related]  

  • 18. HER2-positive breast cancer cells resistant to trastuzumab and lapatinib lose reliance upon HER2 and are sensitive to the multitargeted kinase inhibitor sorafenib.
    Valabrega G; Capellero S; Cavalloni G; Zaccarello G; Petrelli A; Migliardi G; Milani A; Peraldo-Neia C; Gammaitoni L; Sapino A; Pecchioni C; Moggio A; Giordano S; Aglietta M; Montemurro F
    Breast Cancer Res Treat; 2011 Nov; 130(1):29-40. PubMed ID: 21153051
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Epidermal growth factor receptor (HER1) tyrosine kinase inhibitor ZD1839 (Iressa) inhibits HER2/neu (erbB2)-overexpressing breast cancer cells in vitro and in vivo.
    Moulder SL; Yakes FM; Muthuswamy SK; Bianco R; Simpson JF; Arteaga CL
    Cancer Res; 2001 Dec; 61(24):8887-95. PubMed ID: 11751413
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Integrated Exploitation of the Structural Diversity Space of Chemotherapy Drugs to Selectively Inhibit HER2 T798M Mutant in Lung Cancer.
    Wang YW; Zhang HY; Li JS; Wang XW
    Chem Biodivers; 2017 Mar; 14(3):. PubMed ID: 27696725
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.